Novel Frontline Combinations Influence Later-Line Treatment Strategies in SCLC
October 26th 2023While progress in outcomes has been greater in non–small cell lung cancer, recent advances, including molecularly targeted therapies against EGFR and ALK, checkpoint inhibitors that boost immune response, improved staging, and video-assisted surgery have all contributed to progress in treatment of all types of lung cancer, including in SCLC.
Dr Luke on the Background of the KEYNOTE-716 Trial in High-Risk Melanoma
August 18th 2023Jason Luke, MD, FACP, discusses the background of the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma, highlighting previous data from the trial that led to the 36-month follow-up report.
Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC
Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.
Expert Insights on First-line Treatment Strategies in SCLC
An overview of first-line treatment options in SCLC with expert insights on important considerations in guiding treatment selection.
Dr Luke on Results of KEYNOTE-716 of Adjuvant Pembrolizumab in Stage IIB/C Melanoma
June 6th 2023Jason Luke, MD, FACP, discusses the final analysis of distant metastasis–free survival in the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma.
CSCC: Translating Cemiplimab Data Into Practice
April 19th 2023Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.
Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
April 12th 2023A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials
April 12th 2023Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.